Biosimilars vs. Interchangeable Biological Products: FDA Fact Check
XTalks
FEBRUARY 8, 2021
Last year, Biocon Biologics and Mylan announced they’d be seeking interchangeable status for their long-acting insulin product Semglee , developed to be an alternative to Sanofi’s Lantus (insulin glargine). Unlike small-molecule generic drugs, biosimilars do not need to demonstrate bioequivalence to the innovator product.
78 
Let's personalize your content